

Dear WHO Expert Committee,

I am writing to express my strong support for the inclusion of blinatumomab on the WHO Model List of Essential Medicines for Children (EMLc).

Blinatumomab has demonstrated significant clinical benefit in the treatment of acute lymphoblastic leukemia in children. As a bispecific T-cell engager, it provides a targeted and effective option for patients with poor prognosis, many of whom do not respond to conventional chemotherapy. Its inclusion on the EMLc would be a critical step toward improving access to this innovative therapy in low- and middle-income countries, where treatment options are often limited. Including blinatumomab in the EMLc would align with the goals of the WHO Global Initiative for Childhood Cancer (GICC) and help reduce survival disparities by ensuring that essential, high-impact cancer medicines are made more widely available.

I respectfully urge the Committee to give this application full consideration and to support the global effort to expand access to life-saving treatment for children with cancer.

Sincerely,

Federico Antillon, MD, PhD

Pediatric Hematologist Oncologist

Unidad Nacional de Oncología Pediátrica

Guatemala, Guatemala